Evelo Biosciences to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020

Rhea-AI Summary

Evelo Biosciences (Nasdaq: EVLO) announced a conference call on July 30, 2020, at 8:30 a.m. ET to discuss its second quarter 2020 financial results and business highlights. The call will be accessible via dial-in and a live webcast on their website. Evelo is a clinical stage biotechnology company focused on developing oral biologics targeting the small intestinal axis (SINTAX), which influences immune and metabolic systems. Its product candidates include EDP1815, EDP1867, EDP2939 for inflammatory diseases, and EDP1503 for cancer, showcasing their innovative approach to treatment.

Positive

• Evelo is developing four product candidates targeting significant health issues.
• Potential therapeutic benefits for inflammatory diseases and cancer.
• Focus on creating safe and affordable oral biologics.

Negative

• None.

CAMBRIDGE, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 30, 2020 to report its second quarter 2020 financial results and discuss business highlights.

To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 7048016. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

About Evelo Biosciences

Evelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX™, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19, and EDP1503 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.

Contact
Evelo Biosciences
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com

FAQ

What date is Evelo Biosciences' Q2 2020 earnings call?

The Q2 2020 earnings call is scheduled for July 30, 2020.

How can I access the live webcast of Evelo's earnings call?

You can access the live webcast on Evelo's website under the 'News and Events' section.

What is the focus of Evelo Biosciences' research?

Evelo focuses on developing oral biologics that act on SINTAX for therapeutic effects.

What product candidates is Evelo currently developing?

Evelo is developing EDP1815, EDP1867, EDP2939 for inflammatory diseases and EDP1503 for cancer.